What is BridgeBio Pharma's market cap?

BridgeBio Pharma (BBIO) has a market capitalization of $15.3B and trades on NASDAQ.

What is BridgeBio Pharma's revenue and profitability?

BridgeBio Pharma generated $580.0M in trailing twelve-month revenue with a net loss of $729.9M, representing a net margin of -125.9%. Gross margin stands at 95.1%, with free cash flow of -$445.1M. These figures are based on the Q1 2026 filing.

Who are BridgeBio Pharma's competitors?

BridgeBio Pharma's key competitors include Pfizer, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, and others. These companies compete in similar markets and product categories.

Who does BridgeBio Pharma partner with?

BridgeBio Pharma's notable partners include Bayer, Alexion (AstraZeneca), Kyowa Kirin, and others.

What subsidiaries does BridgeBio Pharma have?

BridgeBio Pharma's subsidiaries include Eidos Therapeutics, Inc., QED Therapeutics, Inc., Calcilytix, Inc., and others.

Where is BridgeBio Pharma headquartered?

BridgeBio Pharma is headquartered in United States of America and employs approximately 556 people. It has been publicly traded since 2019.

BridgeBio Pharma

BBIO

BridgeBio Pharma is a commercial-stage biopharmaceutical company utilizing a decentralized hub-and-spoke operating model to develop and commercialize medicines for genetic diseases.

Market cap

$15.34B+83.7%

Revenue$580.0M+355%

Net income-$729.9M-7.8%

Free cash flow-$445.1M+44.1%

EPS (diluted)-$3.73-5.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$194.5MBeat by $16.4M EPS-$0.84Miss by $0.14

Read the full report

Next report

Aug 4, 2026 (In 3 weeks)

Revenue estimate$220.2M

EPS estimate-$0.64

Financials

Q1 2026

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation & ratios

Valuation

See full

Market cap$15.34B+83.7%

Enterprise value$17.72B+133%

P/S26.5×-9.0×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Current ratio1.5×-3.0×

Segments

By product

See full

Cost of license, services, and royalty revenue$10.3M—

License and services revenue$4.4M—

By segment

See full

Reportable Segment$194.5M—

Competitors

By market cap

Pfizer$137.07B-5.0%

ALN

Alnylam Pharmaceuticals$43.2B-0.2%

Royalty Pharma$25.9B+68.8%

BridgeBio Pharma$15.3B+83.7%

BioMarin Pharmaceuticals$11.5B+4.7%

Tyra Biosciences, Inc.$1.9B+264%

Regenxbio$787.4M+78.8%

PAS

Passage Bio, Inc.$15.5M-46.0%

By revenue growth

BridgeBio Pharma+355%

ALN

Alnylam Pharmaceuticals+82.6%

BioMarin Pharmaceuticals+9.9%

Royalty Pharma+7.8%

Pfizer+1.4%

Regenxbio-44.0%

By net margin

Royalty Pharma33.9%-14.4pp

BioMarin Pharmaceuticals16.82%+1.0pp

Pfizer15.65%+6.3pp

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

BridgeBio Pharma-125.85%+405pp

Regenxbio-330.23%-230pp

Profile

BridgeBio Pharma is a commercial-stage biopharmaceutical company utilizing a decentralized hub-and-spoke operating model to develop and commercialize medicines for genetic diseases. The company focuses on translating advances in genetic science into therapies for underserved patient populations with clear genetic drivers. Its portfolio-based approach aims to achieve clinical proof-of-concept with high capital efficiency across a broad range of therapeutic programs.

Competitive position

BridgeBio maintains a leading position in the ATTR-CM market with the first near-complete TTR stabilizer and operates a highly efficient R&D engine that produces a high volume of IND submissions relative to capital invested.

GeographiesUnited States, European Union, Japan, United Kingdom

Customer segmentsRare disease patients, Cardiologists, Endocrinologists, Pediatric specialists

Business modelR&D-focused, Direct-to-market, Licensing and Royalties

SuppliersContract Manufacturing Organizations (CMOs), Academic and research institutions for IP licensing, Raw material suppliers

CustomersSpecialty pharmacies, Specialty distributors, Government healthcare programs (Medicare/Medicaid), Commercial insurance payors

CountryUnited States of America

Listed2019

Employees556.0

CEONeil Kumar

SectorHealthcare

IndustryBiotechnology

Websitebridgebio.com

FilingsSEC EDGAR

Ask your AI about BridgeBio Pharma.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's market cap?: BridgeBio Pharma (BBIO) has a market capitalization of $15.3B and trades on NASDAQ.
What is BridgeBio Pharma's revenue and profitability?: BridgeBio Pharma generated $580.0M in trailing twelve-month revenue with a net loss of $729.9M, representing a net margin of -125.9%. Gross margin stands at 95.1%, with free cash flow of -$445.1M. These figures are based on the Q1 2026 filing.
Who are BridgeBio Pharma's competitors?: BridgeBio Pharma's key competitors include Pfizer, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, and others. These companies compete in similar markets and product categories.
Who does BridgeBio Pharma partner with?: BridgeBio Pharma's notable partners include Bayer, Alexion (AstraZeneca), Kyowa Kirin, and others.
What subsidiaries does BridgeBio Pharma have?: BridgeBio Pharma's subsidiaries include Eidos Therapeutics, Inc., QED Therapeutics, Inc., Calcilytix, Inc., and others.
Where is BridgeBio Pharma headquartered?: BridgeBio Pharma is headquartered in United States of America and employs approximately 556 people. It has been publicly traded since 2019.